Trials / Completed
CompletedNCT02583165
A Study in Adult Subjects With Select Advanced Solid Tumors
A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of MEDI1873 in adult subjects with selected advanced solid tumors.
Detailed description
This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm dose-escalation study of MEDI1873 to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and anti-tumor activity in adult subjects with advanced solid tumor malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI1873 | Subjects will receive MEDI1873 by intravenous administration |
Timeline
- Start date
- 2015-11-09
- Primary completion
- 2018-12-19
- Completion
- 2018-12-19
- First posted
- 2015-10-22
- Last updated
- 2019-01-08
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02583165. Inclusion in this directory is not an endorsement.